author-photo

Christoph Klade

Intercell

56

Papers

1420

Citations

Citation Trend

Filter By

Papers (38) Sort By

Journal Conference Others

Polycythemia Vera Patients Respond Better to Ropeginterferon Alfa-2b Than HU/BAT Irrespective of Pretreatment or Mutational Status; Results from 5 Years' Treatment in a Randomized, Controlled Setting in the PROUD-PV/Continuation-PV Trials

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups.

2020
Show All
- Source
- Cite
- Save
Citations (1)
Germline Genetic Factors Influence Outcome of Interferon Alpha Therapy in Polycythemia Vera.

2020 Blood
Show All
- Source
- Cite
- Save
Citations (8)
Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: 5-Year Results from a Randomized Controlled Study and Its Extension

2020 Blood
Show All
- Source
- Cite
- Save
Citations (4)
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study

2020 The Lancet Haematology
Show All
- Source
- Cite
- Save
Citations (84)
Thromboembolic Risk Reduction and High Rate of Complete Molecular Response with Long-Term Use of Ropeginterferon Alpha-2b in Polycythemia Vera: Results from a Randomized Controlled Study

2019 Blood
Show All
- Source
- Cite
- Save
Citations (3)
Germline Genetic Factors Affecting Interferon Alpha Therapy in Polycythemia Vera

2019 Blood
Show All
- Source
- Cite
- Save
Citations (0)
MAINTENANCE OF RESPONSE IN LONG-TERM TREATMENT WITH ROPEGINTERFERON ALFA-2B (BESREMI®) VS. HYDROXYUREA IN POLYCYTHEMIA VERA PATIENTS (PROUD/CONTINUATION-PV PHASE III TRIALS): PS1457

2019
Show All
- Source
- Cite
- Save
Citations (1)
Pharmacokinetics of a Novel Anagrelide Extended‐Release Formulation in Healthy Subjects: Food Intake and Comparison With a Reference Product

2018 Clinical pharmacology in drug development
Show All
- Source
- Cite
- Save
Citations (2)
Phase 3 trial team-ET in 106 high-risk Essential Thrombocythemia patients, demonstrating non-inferiority of anathromb, a novel, extended-release anagrelide formulation, to the licensed comparator

2016
Show All
- Source
- Cite
- Save
Citations (0)